Table 5. Results from Bayesian latent class network meta-analysis in all regions.
Sensitivity and specificity in pediatric patients compared with a blood culture reference test or theoretical bone marrow culture test.
| Diagnostic accuracy against blood culture | Diagnostic accuracy against latent class bone marrow culture | |||
|---|---|---|---|---|
| Test | Sensitivity (95%CI) | Specificity (95%CI) | Sensitivity (Scenario min-max) | Specificity (scenario min-max) |
| Antibody (Enterocheck WB, IgM) | 85% (73% - 94%) | 73% (94% - 89%) | 39% (30% - 53%) | 97% (96% - 97%) |
| Antibody (ELISA, IgA) | 91% (79% - 98%) | 79% (98% - 79%) | 64% (51% - 78%) | 99% (99% - 99%) |
| Antibody (ELISA, IgG) | 50% (44% - 57%) | 44% (57% - 56%) | 53% (46% - 56%) | 85% (80% - 85%) |
| Antibody (ELISA, IgM) | 66% (60% - 71%) | 60% (71% - 77%) | 62% (54% - 70%) | 98% (96% - 98%) |
| Antibody (ELISA, IgG or IgM) | 74% (56% - 87%) | 56% (87% - 80%) | 47% (37% - 58%) | 93% (91% - 93%) |
| Antibody (ELISA, total Ig) | 87% (74% - 95%) | 74% (95% - 75%) | 86% (84% - 88%) | 100% (99% - 100%) |
| Antibody (Lateral flow, IgG) | 98% (90% - 100%) | 90% (100% - 78%) | 93% (72% - 98%) | 93% (92% - 94%) |
| Antibody (Lateral flow, IgM or IgG) | 69% (57% - 79%) | 57% (79% - 71%) | 59% (52% - 65%) | 93% (91% - 94%) |
| Antibody (Lateral flow, IgM) | 55% (39% - 70%) | 39% (70% - 98%) | 13% (11% - 17%) | 99% (99% - 99%) |
| Antibody (TUBEX, IgM) | 66% (59% - 73%) | 59% (73% - 85%) | 44% (35% - 58%) | 98% (98% - 98%) |
| Antibody (Typhidot, IgG) | 13% (4% - 30%) | 4% (30% - 33%) | 37% (23% - 52%) | 73% (72% - 78%) |
| Antibody (Typhidot, IgM) | 77% (70% - 83%) | 70% (83% - 60%) | 80% (70% - 85%) | 95% (92% - 96%) |
| Antigen (RDT) | 91% (59% - 100%) | 59% (100% - 96%) | 55% (42% - 75%) | 95% (94% - 96%) |
| Antibody (Typhidot, IgM or IgG) | 65% (44% - 83%) | 44% (83% - 66%) | 91% (86% - 93%) | 86% (86% - 87%) |
| Antigen (Reverse Passive Hemagluttination) | 100% (93% - 100%) | 93% (100% - 76%) | 99% (72% - 100%) | 92% (91% - 93%) |
| Antigen (TUBEX TP, O12) | 100% (88% - 100%) | 88% (100% - 100%) | 77% (55% - 100%) | 99% (99% - 99%) |
| Diazo | 87% (69% - 96%) | 69% (96% - 86%) | 56% (46% - 74%) | 94% (92% - 94%) |
| nested PCR (blood) | 45% (34% - 55%) | 34% (55% - 83%) | 39% (36% - 43%) | 94% (94% - 94%) |
| PCR/DNA | 52% (41% - 63%) | 41% (63% - 94%) | 25% (21% - 34%) | 99% (99% - 99%) |
| Widal slide (O) 1:80 (O) | 71% (63% - 78%) | 63% (78% - 98%) | 60% (53% - 66%) | 98% (98% - 98%) |
| Widal slide (H) 1:160 (H) | 86% (79% - 91%) | 79% (91% - 98%) | 79% (69% - 82%) | 98% (98% - 99%) |
| Widal slide (O or H) 1:160 (O or H) | 71% (60% - 80%) | 60% (80% - 59%) | 66% (62% - 74%) | 90% (90% - 91%) |
| Widal (O) 1:80 (O) | 53% (36% - 69%) | 36% (69% - 86%) | 29% (28% - 34%) | 91% (91% - 92%) |
| Widal (O) 1:160 (O) | 70% (51% - 85%) | 51% (85% - 94%) | 46% (41% - 55%) | 96% (95% - 96%) |
| Widal (H) 1:160 (H) | 30% (15% - 49%) | 15% (49% - 98%) | 19% (14% - 21%) | 97% (96% - 97%) |
| Widal (O or H) 1:80 (O or H) | 92% (75% - 99%) | 75% (99% - 100%) | 75% (73% - 76%) | 99% (99% - 99%) |
| Widal (H) 1:200 (H), 1:100 (O) | 30% (15% - 49%) | 15% (49% - 91%) | 19% (15% - 22%) | 93% (91% - 94%) |
| Antibody (TPT test, S.Typhi specific IgA) | 100% (94% - 100%) | 94% (100% - 69%) | 94% (76% - 100%) | 97% (96% - 97%) |
| Widal (O) 1:180 (O) | 61% (54% - 68%) | 54% (68% - 51%) | 67% (67% - 76%) | 90% (87% - 97%) |
| Widal (H) 1:80 (H) | 75% (48% - 93%) | 48% (93% - 95%) | 20% (15% - 28%) | 97% (96% - 97%) |